The aim of the study was to investigate the expressions of miR-200 family, and miR-16 in patients with triple negative breast cancer (TNBC) and analyze their relationship with clinicopathological characteristics and their impacts on overall survival.
The expression levels of members in the miR-200 family, including miR-200b, miR-141, miR-429, and miR-16 were examined by real-time quantitative reverse transcription polymerase chain reaction (real-time qRT-PCR) in tumor samples. Associations of their expression with clinicopathological factors and overall survival were statistically evaluated.
We found that the expression levels of miR-16 were associated with lymph node metastasis, and stage (p = 0.004, and p = 0.004 respectively) but not miR-141, miR-429, and miR-200b (p> 0.05 respectively). However, there were no statistically significant differences between the expression levels of miR-16, miR-141, miR-429, and miR-200b and histological grade, and tumor diameter (p> 0.05 respectively). The Kaplan-Meier analyses showed that high expression of miR-16 was associated with longer OS (p = 0.0001). However, in this study, no significant differences in OS were observed according to expression levels of remaining miRNA, age, lymph node metastasis, grade, and stage. The median OS for TNBC patients with low miR-16 expression was 16 Â± 9.3 months. TNBC patients with the high expression of miR-16 did not reach the median OS time. Then, multivariate cox regression analysis showed that miR-16 expression was independent prognostic factor for the TNBC patients (p = 0.007, 95 % CI 2.21-34.23, Relative Risk 5,46).
However, in conclusion, despite the retrospective design and the small patient size we found that expression levels of miR-16 were associated with lymph node metastasis, stage, and high expression of miR-16 was associated with longer OS in patients with TNBC. Taken together, our study data suggest that miR-16 overexpression might be useful as a potential therapeutic target in patients with TNBC, which is an aggressive and fatal breast cancer type.
Clinical trial identification
All authors have declared no conflicts of interest.